Patents by Inventor Martha Susan Hayden-Ledbetter

Martha Susan Hayden-Ledbetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING CONSTRUCTS AND METHODS FOR USE THEREOF
    Publication number: 20100279932
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, PETER AMSTRONG THOMPSON
  • Binding constructs and methods for use thereof
    Patent number: 7754209
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgGI hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: July 13, 2010
    Assignee: Trubion Pharmaceuticals
    Inventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
  • Binding Domain Fusion Protein
    Publication number: 20080181892
    Abstract: The present invention relates to constructs and methods for the treatment of diseases, disorders and conditions, including those relating to or involving autoimmune disorders, inflammation, bacterial, fungal, and viral infections, and diseases caused by or involving uncontrolled or abnormal proliferation of cells, including cancer.
    Type: Application
    Filed: August 10, 2005
    Publication date: July 31, 2008
    Applicant: Trubion Pharmaceuticals
    Inventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Peter Armstrong Thompson, Philip H. Tan